| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2013: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2012: ¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000)
|
|---|
| Outline of Final Research Achievements |
SAV1, a component of the Hippo pathway, has been reported to be involved in malignant transformation of clear cell renal cell carcinoma (ccRCC). In this study, we found that re-expression of SAV1 inhibited RCC cell proliferation in vitro. In addition, immunohistochemistry frequently demonstrated nuclear localization of YAP1 in ccRCC cases with SAV1. Furthermore, tumors injected with SAV1 stable cell lines showed a decrease of tumor size and growth rate, compared with those of control. Pathway analysis revealed that TGFβ signaling was found to be inhibited in tumors with SAV1 stable cell lines. Based on these data, it is suggested that Hippo pathway including SAV1 acts as tumor suppressor, and downregulation of SAV1 is implicated in malignant formation in ccRCC through TGF beta signaling.
|
